series-a
Stage
2016
Founded
5
Investors
About
Vir Biotechnology is a clinical-stage biotechnology company developing antibody-based medicines and leveraging immune-system-focused technologies, including a next-generation antibody platform and the PRO-XTEN masking technology, to create therapies for infectious diseases and oncology.
Explore Vir Biotechnology's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.